Avanos Medical, Inc. (NYSE:AVNS) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its stake in Avanos Medical, Inc. (NYSE:AVNS) by 7.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 523,494 shares of the company’s stock after selling 44,734 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.14% of Avanos Medical worth $12,580,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AVNS. Azzad Asset Management Inc. ADV lifted its position in shares of Avanos Medical by 8.5% during the 2nd quarter. Azzad Asset Management Inc. ADV now owns 28,521 shares of the company’s stock worth $568,000 after buying an additional 2,223 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of Avanos Medical by 19.5% in the 2nd quarter. Natixis Advisors LLC now owns 18,878 shares of the company’s stock valued at $376,000 after purchasing an additional 3,077 shares during the last quarter. Paradice Investment Management LLC raised its position in Avanos Medical by 5.4% during the 2nd quarter. Paradice Investment Management LLC now owns 1,344,949 shares of the company’s stock worth $26,791,000 after buying an additional 69,389 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Avanos Medical in the 2nd quarter worth $444,000. Finally, American Century Companies Inc. boosted its holdings in shares of Avanos Medical by 12.1% in the second quarter. American Century Companies Inc. now owns 82,930 shares of the company’s stock valued at $1,652,000 after acquiring an additional 8,929 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Stock Down 2.2 %

AVNS opened at $18.47 on Monday. Avanos Medical, Inc. has a one year low of $17.39 and a one year high of $25.36. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The business’s fifty day moving average is $20.77 and its two-hundred day moving average is $21.49. The company has a market cap of $848.88 million, a price-to-earnings ratio of 54.32 and a beta of 0.95.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered Avanos Medical from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 3rd.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.